Medtronic plc | Large-cap | Healthcare
87,92 US$
0,74 %
| Medtronic plc Stock Comparison:
Medtronic plc vs Abbott LaboratoriesMedtronic plc vs Boston ScientificMedtronic plc vs StrykerMedtronic plc vs Edwards LifesciencesMedtronic plc vs DexcomMedtronic plc vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 32,4B
Gross Profit 21,1B 65,34 %
Operating Income 5,5B 17,06 %
Net Income 3,7B 11,45 %
EPS (Diluted) 2,76 US$

Balance Sheet Metrics

Total Assets 90,0B
Total Liabilities 39,6B
Shareholders Equity 50,4B
Debt to Equity 0,78

Cash Flow Metrics

Operating Cash Flow 5,9B
Free Cash Flow 5,2B

Revenue & Profitability Trend

Income Statement

Metric 2024 2023 2022 2021 2020
Revenue 32,4B 31,2B 31,7B 30,1B 28,9B
Cost of Goods Sold 11,2B 10,7B 10,1B 10,5B 9,4B
Gross Profit 21,1B 20,5B 21,5B 19,6B 19,5B
Operating Expenses 13,9B 13,0B 13,9B 13,0B 12,5B
Operating Income 5,5B 5,8B 5,9B 4,9B 5,2B
Pre-tax Income 4,8B 5,4B 5,5B 3,9B 4,1B
Income Tax 1,1B 1,6B 456,0M 265,0M -751,0M
Net Income 3,7B 3,8B 5,1B 3,6B 4,8B
EPS (Diluted) 2,76 US$ 2,82 US$ 3,73 US$ 2,66 US$ 3,54 US$

Income Statement Trend

Balance Sheet

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 21,9B 21,7B 23,1B 22,5B 22,0B
Non-Current Assets 68,0B 69,3B 67,9B 70,5B 68,7B
Total Assets 90,0B 90,9B 91,0B 93,1B 90,7B
Liabilities
Current Liabilities 10,8B 9,1B 12,4B 8,5B 10,4B
Non-Current Liabilities 28,8B 30,2B 25,9B 33,0B 29,5B
Total Liabilities 39,6B 39,3B 38,3B 41,5B 39,8B
Equity
Total Shareholders Equity 50,4B 51,7B 52,7B 51,6B 50,9B

Balance Sheet Composition

Cash Flow Statement

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 3,7B 3,8B 5,1B 3,6B 4,8B
Operating Cash Flow 5,9B 5,2B 6,6B 5,3B 6,8B
Investing Activities
Capital Expenditures -1,6B -1,5B -1,4B -1,4B -1,2B
Investing Cash Flow -2,4B -3,5B -1,7B -2,9B -3,2B
Financing Activities
Dividends Paid -3,7B -3,6B -3,4B -3,1B -2,9B
Financing Cash Flow -4,4B -7,2B -5,3B -7,3B -4,2B
Free Cash Flow 5,2B 4,6B 6,0B 4,9B 6,0B

Cash Flow Trend

Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 24,17
Forward P/E 14,92
Price to Book 2,33
Price to Sales 3,34
PEG Ratio 14,92

Profitability Ratios

Profit Margin 13,90 %
Operating Margin 21,36 %
Return on Equity 9,51 %
Return on Assets 4,61 %

Financial Health

Current Ratio 1,85
Debt to Equity 59,09
Beta 0,82

Per Share Data

EPS (TTM) 3,61 US$
Book Value per Share 37,46 US$
Revenue per Share 26,09 US$

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
mdt 111,9B 24,17 2,33 9,51 % 13,90 % 59,09
Abbott Laboratories 232,9B 17,38 4,77 30,65 % 31,89 % 27,09
Boston Scientific 147,6B 72,80 6,64 9,50 % 11,58 % 52,16
Stryker 144,2B 50,99 6,89 14,26 % 12,31 % 82,92
Edwards Lifesciences 44,1B 31,05 4,35 16,51 % 75,71 % 6,86
Dexcom 32,1B 61,65 14,18 23,72 % 12,90 % 113,97

Financial data is updated regularly. All figures are in the company's reporting currency.